The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to …

Biosensors are of great significance because of their capability to resolve a potentially large
number of analytical problems and challenges in very diverse areas such as defense …

Alzheimer's Disease (AD) is becoming increasingly prevalent across the globe, and various
diagnostic and detection methods have been developed in recent years. Several techniques …

Context Blood-based analytes may be indicators of pathological processes in Alzheimer
disease (AD). Objective To identify plasma proteins associated with AD pathology using a …

Parkinson's disease (PD) is the second most common neurodegenerative disorder mostly
affecting the aging population over sixty. Cardinal symptoms including, tremors, muscle …

MicroRNAs (miRNAs) are small, abundant RNA molecules that constitute part of the cell's
non-coding RNA “dark matter.” In recent years, the discovery of miRNAs has revolutionised …

Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease with a complex
clinical course characterized by inflammation, demyelination, and axonal degeneration …

Neurodegenerative diseases (NDs) are characterised by progressive dysfunction of
synapses, neurons, glial cells and their networks. Neurodegenerative diseases can be …

There is a pressing need for biomarkers to diagnose Parkinson's disease (PD), assess
disease severity, and prognosticate course. Various types of biologic specimens are …

Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …